Listar por autor "Díaz-Regañón, Jazmín"

Mostrando ítems 1-2 de 2

    • Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain 

      Ferrer, Ricard; Fariñas, María del Carmen; Maseda, Emilio; Salavert, Miguel; Bou, Germán; Díaz-Regañón, Jazmín; López, Diego; Lozano, Virginia; Gómez-Ulloa, David; Fenoll, Raquel; Lara, Nuria; McCann, Eilish (Sociedad Española de Quimioterapia, 2021-11-22)
      [Abstract] Objective: Carbapenem-resistant Gram-negative (CRGN) infections are a major public health problem in Spain, often implicated in complicated, healthcare-associated infections that require the use of potentially ...

    • Imipenem-relebactam susceptibility in enterobacterales isolates recovered from ICU patients from Spain and Portugal (SUPERIOR and STEP studies) 

      Hernández-García, Marta; García-Castillo, María; Bou, Germán; Cercenado, Emilia; Delgado-Valverde, Mercedes; Oliver, Antonio; Pitart, Cristina; Rodríguez-Lozano, Jesús; Tormo, Nuria; Melo-Cristino, José; Pinto, Margarida Feijó; Gonçalves, Elsa; Alves, Valquíria; Vieira, Ana Raquel; Ramalheira, Elmano; Sancho, Luísa; Diogo, José; Ferreira, Rui; Cruz, Hugo; Chaves, Catarina; Duarte, Joana; Pássaro, Leonor; Díaz-Regañón, Jazmín; Cantón, Rafael (American Society of Microbiology, 2022-08-31)
      [Abstract] Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 ...